BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Loading contract…
Centralised Adult Flu Procurement | UKGovscan
Loading contract…
PIPELINEPipeline notice · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencyRef ocds-h6vhtk-04b1c0
This procurement was divided into 1 lots, each awarded separately.
Lots
1
Lot
Value
Status
Lot 1
-
planned
Key Dates
Published
3 October 2025
Tender Open
-
Tender Deadline
-
Award Date
-
Contract Start
-
Contract End
-
Notice Amendments
Changes the buyer published to this notice after it first appeared.
Amendment 1
Change (II.2.4.1): UKHSA, as the potential Contracting Authority, are leading the pre-market engagement activity with the purpose to:• Gain a better understanding of the ‘as-is’ adult NHS flu programme from the perspective of vaccine manufacturers and wholesalers • Understand what impact centralising the procurement and/or supply of adult flu vaccine would potentially have on the market including current capability and capacity; options under consideration includeo Procuring Adult Flu Vaccines using a Centralised Framework Contracto UKHSA Procuring Adult Flu Vaccines and maintaining existing supply and distribution methodso UKHSA Procuring Adult Flu Vaccines and ingesting supply centrally for distribution o Maintaining the status quo• Explore any potential barriers, opportunities, benefits or risks there may be with a central procurement and/or supply approach.• Have an open dialogue with the market to ensure a full understanding of the future landscape.The market engagement will take the form of a questionnaire available via our e-procurement system, which you will be asked to complete and return. Once returned, you may be invited for a 1:1 meeting with the project team to discuss your answers and provide clarification. It is anticipated that these meetings will take place during November/December 2024.Who would we like to hear from?We are keen to engage with those suppliers who already have a licenced adult flu vaccine and/or have experience of the UK adult flu market, who have an adult flu vaccine in development, or who may have an adult flu vaccine in their future product development pipeline, and with medical logistics providers both wholesale and distribution.How to participate?The opportunity will be available on the Atamis eTendering system, access here: https://atamis-1928.my.site.com/s/Welcome . If you do not already have an account you can easily register for one via the same link. You will then be able to search for this opportunity and access the questionnaire and any other related documents. Please note that all correspondence must be conducted through the Atamis system. The response window will close at 5pm on Sunday 17th November 2024. → UKHSA, as the potential Contracting Authority, are leading the pre-market engagement activity with the purpose to:• Gain a better understanding of the ‘as-is’ adult NHS flu programme from the perspective of vaccine manufacturers and wholesalers • Understand what impact centralising the procurement and/or supply of adult flu vaccine would potentially have on the market including current capability and capacity; options under consideration includeo Procuring Adult Flu Vaccines using a Centralised Framework Contracto UKHSA Procuring Adult Flu Vaccines and maintaining existing supply and distribution methodso UKHSA Procuring Adult Flu Vaccines and ingesting supply centrally for distribution o Maintaining the status quo• Explore any potential barriers, opportunities, benefits or risks there may be with a central procurement and/or supply approach.• Have an open dialogue with the market to ensure a full understanding of the future landscape.The market engagement will take the form of a questionnaire available via our e-procurement system, which you will be asked to complete and return. Once returned, you may be invited for a 1:1 meeting with the project team to discuss your answers and provide clarification. It is anticipated that these meetings will take place during November/December 2024.Who would we like to hear from?We are keen to engage with those suppliers who already have a licenced adult flu vaccine and/or have experience of the UK adult flu market, who have an adult flu vaccine in development, or who may have an adult flu vaccine in their future product development pipeline, and with medical logistics providers both wholesale and distribution.How to participate?The opportunity will be available on the Atamis eTendering system, access here: https://atamis-1928.my.site.com/s/Welcome . If you do not already have an account you can easily register for one via the same link. You will then be able to search for this opportunity and access the questionnaire and any other related documents. Please note that all correspondence must be conducted through the Atamis system. The response window will close at 5pm on Friday 29th November 2024.
Amendment 2
The purpose of this notice is to provide an update regarding the Government's consideration of the Centralisation of Adult Flu Vaccine. We would like to express our gratitude for your ongoing interest and engagement in this matter.This project is characterised by significant complexity, and consequently, we are robustly exploring all available options to ensure efficient and successful delivery in alignment with the NHS Vaccination Strategy (2023), while also ensuring the engagement of all relevant stakeholders.Furthermore, to ensure market stability and to avoid any undue impact on the existing programme in the upcoming seasons, we can confirm that the proposed central procurement and distribution of Adult Flu Vaccine, which is subject to consultation with primary care representative bodies, will not aim to commence until Winter 2028 to 2029 at the earliest.We will ensure that sufficient notice is given for any proposed changes that are to be implemented.To note: This statement does not preclude the outcome of the consultation with the primary care representative bodies.
Amendment 3
The purpose of this notice is to provide an update regarding the Government's consideration of the Centralisation of Adult Flu Vaccine. We would like to express our gratitude for your ongoing interest and engagement in this matter. This project is characterised by significant complexity, and consequently, we are robustly exploring all available options to ensure efficient and successful delivery in alignment with the NHS Vaccination Strategy (2023), while also ensuring the engagement of all relevant stakeholders. Furthermore, to ensure market stability and to avoid any undue impact on the existing programme in the upcoming seasons, we can confirm that the proposed central procurement and distribution of Adult Flu Vaccine, which is subject to consultation with primary care representative bodies, will not aim to commence until Winter 2029 to 2030 at the earliest. We will ensure that sufficient notice is given for any proposed changes that are to be implemented. To note: This statement does not preclude the outcome of the consultation with the primary care representative bodies.
Procurement Details
Method
–
Method Details
–
Main category
Goods
Category
–
Delivery location
UK
Open under
WTO Government Procurement Agreement
Buyer Reference
C310432
Legal Basis
Public Contracts Regulations 2015 (EU Directive 2014/24)